JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Della Paschoa, O. E.
Right arrow Articles by Danhof, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Della Paschoa, O. E.
Right arrow Articles by Danhof, M.

Vol. 284, Issue 2, 460-466, February 1998

Pharmacokinetic-Pharmacodynamic Modeling of the Anticonvulsant and Electroencephalogram Effects of Phenytoin in Rats

O. E. Della Paschoa, J. W. Mandema, R. A. Voskuyl and M. Danhof

Leiden/Amsterdam Center for Drug Research, Division of Pharmacology, University of Leiden, University of Leiden, P.O. Box. 9503, 2300 RA Leiden, The Netherlands (O.E.D.P., M.D.), Stanford University School of Medicine, Department of Anesthesia, Palo Alto, California (J.W.M.) and Instituut voor Epilepsiebestrijding, Heemstede, The Netherlands (R.A.V.)

In this study a pharmacokinetic-pharmacodynamic model is proposed for drugs with nonlinear elimination kinetics. We applied such an integrated approach to characterize the pharmacokinetic-pharmacodynamic relationship of phenytoin. In parallel, the anticonvulsant effect and the electroencephalogram (EEG) effect were used to determine the pharmacodynamics. Male Wistar-derived rats received a single intravenous dose of 40 mg · kg-1 phenytoin. The increase in the threshold for generalized seizure activity (TGS) was used as the anticonvulsant effect and the increase in the total number of waves in the 11.5 to 30 Hz frequency band was taken as the EEG effect measure. Phenytoin pharmacokinetics was described by a saturation kinetics model with Michaelis-Menten elimination. Vmax and Km values were, respectively, 386 ± 31 µg · min-1 and 15.4 ± 2.2 µg · ml-1 for the anticonvulsant effect in the cortical stimulation model and 272 ± 31 µg · min-1 and 5.9 ± 0.7 µg · ml-1 for the EEG effect. In both groups, a delay to the onset of the effect was observed relative to plasma concentrations. The relationship between phenytoin plasma concentrations and effect site was estimated by an equilibration kinetics routine, yielding mean ke0 values of 0.108 and 0.077 min-1 for the anticonvulsant and EEG effects, respectively. The EEG changes in the total number of waves could be fitted by the sigmoid Emax model, but Emax values could not be estimated for the nonlinear relationship between concentration and the increase in TGS. An exponential equation (E = E0 + Bn · Cn) derived from the sigmoid Emax model was applied to describe the concentration-anticonvulsant effect relationship, under the assumption that Emax values cannot be reached within acceptable electric stimulation levels. This approach yielded a coefficient (B) of 2.0 ± 0.4 µA · ml · µg-1 and an exponent (n) of 2.7 ± 0.9. The derived EC50 value of 12.5 ± 1.3 µg · ml-1 for the EEG effect coincides with the "therapeutic range" in humans.


0022-3565/98/2842-0460$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
E. A. van Vliet, R. van Schaik, P. M. Edelbroek, R. A. Voskuyl, S. Redeker, E. Aronica, W. J. Wadman, and J. A. Gorter
Region-Specific Overexpression of P-glycoprotein at the Blood-Brain Barrier Affects Brain Uptake of Phenytoin in Epileptic Rats
J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 141 - 147.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
A. Limosin, A. Dupuis, I. Lamarche, O. Mimoz, J. Paquereau, and W. Couet
Pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of imipenem in rats with experimental hypovolaemia or endotoxaemia
J. Antimicrob. Chemother., July 1, 2004; 54(1): 187 - 192.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
M. Chenel, A. Barbot, A. Dupuis, O. Mimoz, J. Paquereau, S. Bouquet, and W. Couet
Pharmacokinetic-Pharmacodynamic Modeling of the Electroencephalogram Effect of Norfloxacin in Rats
Antimicrob. Agents Chemother., June 1, 2003; 47(6): 1952 - 1957.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Weiss and W. Kang
P-Glycoprotein Inhibitors Enhance Saturable Uptake of Idarubicin in Rat Heart: Pharmacokinetic/Pharmacodynamic Modeling
J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 688 - 694.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
A. Dupuis, A. Limosin, J. Paquereau, O. Mimoz, W. Couet, and S. Bouquet
Pharmacokinetic-Pharmacodynamic Modeling of Electroencephalogram Effect of Imipenem in Rats with Acute Renal Failure
Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3607 - 3609.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
A. Dupuis, W. Couet, J. Paquereau, S. Debarre, A. Portron, C. Jamois, and S. Bouquet
Pharmacokinetic-Pharmacodynamic Modeling of the Electroencephalogram Effect of Imipenem in Healthy Rats
Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1682 - 1687.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.